Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026
Company Deals

Luye Pharma Grants ICI Pakistan Distribution Rights for Schizophrenia Drug Seroquel

Fineline Cube Sep 28, 2022

China-based Luye Pharma Group has reportedly handed over the distribution and marketing rights for its...

Company Medical Device

Sino Medical Sciences Gains Approval for Drug-Eluting Stent System

Fineline Cube Sep 27, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received market...

Company Drug

Tris Pharma and Pediatrix Therapeutics’ ADHD Drug Gains Priority Review in China

Fineline Cube Sep 27, 2022

The Center for Drug Evaluation (CDE) has indicated that the methylphenidate hydrochloride oral sustained-release dry...

Company Drug

Angel Pharmaceuticals Gains CDE Approval for Mupadolimab Phase I/Ib Study

Fineline Cube Sep 27, 2022

China-based Angel Pharmaceuticals Ltd has announced that it has received approval from the Center for...

Company

YiChang HEC Reports Strong Recovery in 2022 Interim Results

Fineline Cube Sep 27, 2022

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report,...

Company

Sino Biopharmaceutical Reports Mixed Results in 2022 Interim Report

Fineline Cube Sep 27, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has released its 2022 interim report, recording revenues of...

Company Deals Drug

Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China

Fineline Cube Sep 27, 2022

Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...

Company

Global Cord Blood Corporation Appoints Liquidators Amid Shareholder Dispute

Fineline Cube Sep 27, 2022

Global Cord Blood Corporation (OTCMKTS: CORBF) has announced that the Grand Court of the Cayman...

Company Deals

Hansoh Pharmaceutical Licenses KiOmedine One for Osteoarthritis Treatment

Fineline Cube Sep 27, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s...

Company Deals

Ubrigene Raises Hundreds of Millions in Series C Financing Round

Fineline Cube Sep 27, 2022

Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy...

Company Medical Device

China’s First Proton Therapy System Approved by NMPA

Fineline Cube Sep 27, 2022

The National Medical Products Administration (NMPA) has approved the proton therapy system developed by Shanghai...

Company Drug

Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296

Fineline Cube Sep 27, 2022

China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I...

Company Drug

Sino Biopharmaceutical’s TDI01 Receives Clinical Trial Approval for COVID-19

Fineline Cube Sep 27, 2022

China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co....

Company

China Resources Pharma Reports Strong Interim Results Amid COVID-19

Fineline Cube Sep 27, 2022

China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report,...

Company Deals

Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development

Fineline Cube Sep 27, 2022

Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration...

Company Drug

Arctic Vision Administers First Injection of ARVN001 for Uveitis Macular Edema

Fineline Cube Sep 26, 2022

China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal...

Company Deals

Synthgene Partners with Micor&Nano for Comprehensive Solutions in Nucleic Acid Drugs

Fineline Cube Sep 26, 2022

China-based Jiangsu Synthgene Biotechnology Co., Ltd has entered into a partnership with compatriot firm Micor&Nano...

Company Deals

ThunderBio Secures Funding from Guangzhou LBP for PCR Innovation

Fineline Cube Sep 26, 2022

ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has...

Company Drug

Fujian Cosunter Receives NMPA Approval for COVID-19 Drug Candidate GST-HG171

Fineline Cube Sep 26, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that it has received approval...

Company Drug

Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study

Fineline Cube Sep 26, 2022

China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the...

Posts pagination

1 … 611 612 613 … 656

Recent updates

  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
  • Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
  • Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
  • China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.